Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow

Inclusion Criteria: * Patients must have genetically confirmed Von Hippel-Lindau (VHL) disease. * At least one measurable VHL-related lesion, which is undergoing surveillance, and patient is not at immediate risk of needing intervention for this or other lesions. Biopsy is not required given the known natural history in the setting of a positive genetic test. (1) Renal: solid mass suspicious for Renal Cell Carcinoma (RCC) \>/= 1 cm or cystic mass \>/= 1 cm; (2) Pancreas: Solid mass \>/= 1cm \& \< 3cm suspicious for neuroendocrine tumor; (3) Brain: asymptomatic hemangioblastoma \> 5mm; (4) Spine: asymptomatic hemangioblastoma, \> 1cm; (5) Eye: asymptomatic peripapillary and/or macular hemangioblastoma, any size. * Allowable prior therapy: (1) Patients having undergone prior therapy for VHL lesions may enroll as long as other criteria are met. Previously radiated lesions may not be considered as target lesions unless they demonstrate unequivocal evidence of growth; (2) Major surgery, chemotherapy or radiation therapy completed \>4 weeks prior to starting the study treatment. * Age \>/= 18 years. Because no dosing or adverse event data are currently available on the use of SU011248/sunitinib malate in patients \<18 years of age, children are excluded from this study but will be eligible for future pediatric single-agent trials, if applicable. * Eastern Cooperative Oncology Group (ECOG) performance status \</= 2 * Patients must have normal organ and marrow function as defined: (…